Publications
5674 Results
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 2691; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
- Year
- 2019
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106, S0112, SWOG-9031, SWOG-9333
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
- Journal / Conference
- Blood (2018) 132 (Supplement 1): LBA-4; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
- Year
- 2019
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E1912
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 842 (American Society of Hematology (Dec 7-10, 2019, Orlando, FL)), oral, abst. 637
- Year
- 2019
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2905
Combined Treatment with Lenalidomide and Epoetin Alfa leads to Durable Responses in patients with Epo-refractory, Lower Risk Non-deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
- Journal / Conference
- Society for Medical Decision Making Annual Meeting (October 20-23, 2019, Portland, OR), poster
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
"Many Views on Value" of National Cancer Institute-Sponsored Randomized Trials
- Journal / Conference
- JAMA Oncology Sep 5. doi: 10.1001/jamaoncol.2019.2664 [Epub ahead of print]
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID31486827
Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then Trust [editorial]
- Journal / Conference
- Journal of Clinical Oncology, Nov 20;37 (33), 3090-3098
- Year
- 2019
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID31553692
- PMC
- PMC7351323
- Study Number(s)
- S1823
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum
- Journal / Conference
- J Clin Oncol 37, 2019 (suppl 7S; abstr 526), poster; ASCO GU Cancers Symposium
- Year
- 2019
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S1823
Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor
- Journal / Conference
- Journal of Clinical Oncology Mar 1;37(7):589-597
- Year
- 2019
- Research Committee(s)
- Myeloma
- PMID
- PMID30653422
- PMC
- PMC6553842
- Study Number(s)
- CTSU/CTN0702
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
- Journal / Conference
- J Clin Oncol 37 (suppl 4; abstr 588); ASCO GI Cancers Symposium (Jan 17-19, 2019, San Francisco, CA), poster session
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 115 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL)), oral
- Year
- 2019
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906